.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PPCOS II randomized trial compared letrozole with clomiphene for ovulation induction in women with polycystic ovary syndrome and infertility. Letrozole produced a higher cumulative live-birth rate and higher ovulation rate than clomiphene, while multiple pregnancy rates were not significantly higher. The findings established letrozole as a preferred first-line ovulation-induction option for many women with PCOS-related anovulatory infertility. For reproductive-medicine practice, the key is to confirm anovulatory PCOS as the dominant infertility factor before treatment, while assessing tubal and male factors as appropriate. Counseling should address treatment cycles, monitoring, multiple-pregnancy risk and the possibility of moving to gonadotropins or IVF when oral ovulation induction is unsuccessful. The trial also illustrates how a relatively simple modification in first-line therapy can improve reproductive outcomes without requiring escalation directly to advanced ART.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PPCOS II randomized trial compared letrozole with clomiphene for ovulation induction in women with polycystic ovary syndrome and infertility. Letrozole produced a higher cumulative live-birth rate and higher ovulation rate than clomiphene, while multiple pregnancy rates were not significantly higher. The findings established letrozole as a preferred first-line ovulation-induction option for many women with PCOS-related anovulatory infertility. For reproductive-medicine practice, the key is to confirm anovulatory PCOS as the dominant infertility factor before treatment, while assessing tubal and male factors as appropriate. Counseling should address treatment cycles, monitoring, multiple-pregnancy risk and the possibility of moving to gonadotropins or IVF when oral ovulation induction is unsuccessful. The trial also illustrates how a relatively simple modification in first-line therapy can improve reproductive outcomes without requiring escalation directly to advanced ART.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
